Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents

Nucleic Acids Res. 2022 Jan 7;50(D1):D1398-D1407. doi: 10.1093/nar/gkab953.


Drug discovery relies on the knowledge of not only drugs and targets, but also the comparative agents and targets. These include poor binders and non-binders for developing discovery tools, prodrugs for improved therapeutics, co-targets of therapeutic targets for multi-target strategies and off-target investigations, and the collective structure-activity and drug-likeness landscapes of enhanced drug feature. However, such valuable data are inadequately covered by the available databases. In this study, a major update of the Therapeutic Target Database, previously featured in NAR, was therefore introduced. This update includes (a) 34 861 poor binders and 12 683 non-binders of 1308 targets; (b) 534 prodrug-drug pairs for 121 targets; (c) 1127 co-targets of 672 targets regulated by 642 approved and 624 clinical trial drugs; (d) the collective structure-activity landscapes of 427 262 active agents of 1565 targets; (e) the profiles of drug-like properties of 33 598 agents of 1102 targets. Moreover, a variety of additional data and function are provided, which include the cross-links to the target structure in PDB and AlphaFold, 159 and 1658 newly emerged targets and drugs, and the advanced search function for multi-entry target sequences or drug structures. The database is accessible without login requirement at:

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Databases, Factual*
  • Drug Discovery / trends*
  • Humans
  • Molecular Targeted Therapy
  • Prodrugs / chemistry
  • Prodrugs / classification*
  • Prodrugs / therapeutic use
  • Structure-Activity Relationship


  • Prodrugs